2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses toxicities associated with immunotherapy agents for the treatment of patients with osteosarcoma.
Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses toxicities associated with immunotherapy agents for the treatment of patients with osteosarcoma.
In adult patients with osteosarcoma, a sample of them have shown minimal signs of pneumonitis, Gordon explains. This is because there is a type of cytokine release syndrome that can cause that, she adds. Moreover, some patients have reported fatigue, as well as diarrhea. However, aside from the associated toxicities, this therapy has shown durable and long-lasting responses in patients with melanoma and non—small cell lung cancer.
Related Content: